Krystal Biotech Crecimiento futuro

Future controles de criterios 5/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Krystal Biotech de 37% y 34.1% por año respectivamente. Se prevé que el BPA crezca en un 36.1% al año. Se espera que la rentabilidad financiera sea de 18.4% en 3 años.

Información clave

37.0%

Tasa de crecimiento de los beneficios

36.1%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	24.2%
Tasa de crecimiento de los ingresos	34.1%
Rentabilidad financiera futura	18.4%
Cobertura de analistas	Good
Última actualización	03 Jun 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

We Think Krystal Biotech (NASDAQ:KRYS) Can Easily Afford To Drive Business Growth

Jan 02

Companies Like Krystal Biotech (NASDAQ:KRYS) Can Afford To Invest In Growth

Sep 06

Are Investors Undervaluing Krystal Biotech, Inc. (NASDAQ:KRYS) By 46%?

Aug 08

We Think Krystal Biotech (NASDAQ:KRYS) Can Afford To Drive Business Growth

May 17

We're Hopeful That Krystal Biotech (NASDAQ:KRYS) Will Use Its Cash Wisely

Jan 30

Krystal Biotech cleared to file EU marketing application for rare skin disease therapy

Sep 22

We Think Krystal Biotech (NASDAQ:KRYS) Can Afford To Drive Business Growth

Aug 30

Krystal Biotech: Solid Performance, Let's Keep Holding

Aug 18

Krystal Biotech GAAP EPS of -$1.10 misses by $0.07

Aug 08

Krystal gets FDA nod to start trial of gene therapy KB407 for cystic fibrosis

Aug 01

Krystal Biotech: High Potential, Buy-At-Dips Stock

May 25

We're Hopeful That Krystal Biotech (NASDAQ:KRYS) Will Use Its Cash Wisely

Apr 20

Krystal Biotech: The Future Looks More And More Derisked

Feb 21

Krystal Biotech Establishes Proof Of Concept With STAR-D Platform; Opens Door For More Skin Indications

Nov 30

Krystal Biotech: A Buy Ahead Of Their Pivotal DEB P3 Trial Readout

Sep 27

Here's Why We're Not Too Worried About Krystal Biotech's (NASDAQ:KRYS) Cash Burn Situation

Sep 25

Companies Like Krystal Biotech (NASDAQ:KRYS) Are In A Position To Invest In Growth

Jun 17

Krystal Biotech EPS misses by $0.16

May 10

Krystal Biotech provides update on pivotal GEM-3 study of B-VEC for DEB

Apr 26

Here's Why We're Not Too Worried About Krystal Biotech's (NASDAQ:KRYS) Cash Burn Situation

Mar 02

Krystal Biotech secures $125 capital via equity raise

Feb 03

Previsiones de crecimiento de beneficios e ingresos

NasdaqGS:KRYS - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	603	249	345	N/A	7
12/31/2025	426	144	240	166	9
12/31/2024	266	63	130	105	10
3/31/2024	96	57	-54	-47	N/A
12/31/2023	51	11	-101	-89	N/A
9/30/2023	9	-30	-119	-104	N/A
6/30/2023	N/A	-140	-130	-102	N/A
3/31/2023	N/A	-135	-152	-111	N/A
12/31/2022	N/A	-140	-154	-101	N/A
9/30/2022	N/A	-130	-188	-99	N/A
6/30/2022	N/A	-115	-182	-87	N/A
3/31/2022	N/A	-104	-137	-54	N/A
12/31/2021	N/A	-70	-116	-48	N/A
9/30/2021	N/A	-58	-70	-35	N/A
6/30/2021	N/A	-52	-52	-35	N/A
3/31/2021	N/A	-43	-45	-30	N/A
12/31/2020	N/A	-32	-41	-26	N/A
9/30/2020	N/A	-27	-35	-25	N/A
6/30/2020	N/A	-22	-29	-23	N/A
3/31/2020	N/A	-20	-28	-22	N/A
12/31/2019	N/A	-19	-25	-19	N/A
9/30/2019	N/A	-17	-21	-15	N/A
6/30/2019	N/A	-16	-18	-13	N/A
3/31/2019	N/A	-13	-14	-10	N/A
12/31/2018	N/A	-11	-12	-9	N/A
9/30/2018	N/A	-9	-9	-8	N/A
6/30/2018	N/A	-11	-7	-7	N/A
3/31/2018	N/A	-10	-6	-6	N/A
12/31/2017	N/A	-8	N/A	-4	N/A
9/30/2017	N/A	-7	N/A	-3	N/A
6/30/2017	N/A	-2	N/A	-2	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (37% al año) de KRYS es superior a la tasa de ahorro (2.4%).

Beneficios vs. Mercado: Se prevé que los beneficios (37% al año) de KRYS crezcan más rápidamente que el mercado US (14.8% al año).

Beneficios de alto crecimiento: Se espera que los beneficios de KRYS crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (34.1% al año) de KRYS crezcan más rápidamente que los del mercado US (8.7% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (34.1% al año) de KRYS crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de KRYS sea baja dentro de 3 años (18.4%).

Krystal Biotech Crecimiento futuro

Future controles de criterios 5/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Consensus EPS estimates increase by 16%

Consensus EPS estimates increase by 11%

Price target increased by 14% to US$176

Forecast breakeven date moved forward to 2024

Consensus revenue estimates decrease by 11%, EPS upgraded

Consensus revenue estimates decrease by 11%, EPS upgraded

Recent updates

Founder notifies of intention to sell stock

Independent Director notifies of intention to sell stock

Krystal Biotech's (NASDAQ:KRYS) Earnings Might Be Weaker Than You Think

Consensus EPS estimates increase by 16%

Krystal Biotech, Inc. to Report Q1, 2024 Results on May 06, 2024

Krystal Biotech, Inc Announces First Patient Dosed in Phase 1 Clinical Trial of Inhaled KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors of the Lung

Consensus EPS estimates increase by 11%

Krystal Biotech, Inc., Annual General Meeting, May 17, 2024

Founder notifies of intention to sell stock

Executive VP & Chief Accounting Officer notifies of intention to sell stock

Krystal Biotech's Future Brightens With Vyjuvek's Robust Launch

Price target increased by 14% to US$176

New minor risk - Share price stability

Forecast breakeven date moved forward to 2024

Krystal Biotech, Inc. to Report Q4, 2023 Results on Feb 26, 2024

Krystal Biotech: Ready For Launch

Executive VP & Chief Accounting Officer notifies of intention to sell stock

Krystal Biotech Receives Permanent J-Code (J3401) for VYJUVEK®

We Think Krystal Biotech (NASDAQ:KRYS) Can Easily Afford To Drive Business Growth

Founder notifies of intention to sell stock

Krystal Biotech Announces EMA Validation of Marketing Authorization Application for Vyjuvek for the Treatment of Dystrophic Epidermolysis Bullosa

Krystal Biotech Announces EMA Validation of Marketing Authorization Application for Vyjuvek for the Treatment of Dystrophic Epidermolysis Bullosa

Consensus revenue estimates decrease by 11%, EPS upgraded

Krystal Biotech, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Consensus revenue estimates decrease by 11%, EPS upgraded

Krystal Biotech, Inc. Announces FDA Clearance of Investigational New Drug Application for KB408 for Treatment of Type 1 Alpha-1 Antitrypsin Deficiency

Founder notifies of intention to sell stock

Companies Like Krystal Biotech (NASDAQ:KRYS) Can Afford To Invest In Growth

Consensus revenue estimates increase by 28%

Are Investors Undervaluing Krystal Biotech, Inc. (NASDAQ:KRYS) By 46%?

Price target increased by 8.8% to US$148

Krystal Biotech, Inc. Announces Pipeline Expansion into Oncology and FDA Acceptance of IND Application for Lead Oncology Candidate KB707

Krystal Biotech, Inc.(NasdaqGM:KRYS) dropped from Russell Small Cap Comp Value Index

Lead Independent Director recently sold US$6.4m worth of stock

Executive VP & Chief Commercial Officer exercised options and sold US$813k worth of stock

Founder recently sold US$2.9m worth of stock

Founder notifies of intention to sell stock

FDA Approves New Product Utilizing Berkshire Sterile Excipient Gel to Treat 'Butterfly Children'

Consensus revenue estimates increase by 28%

Krystal Biotech, Inc. announced that it expects to receive $159.999933 million in funding from Avoro Capital Advisors LLC, Redmile Group, LLC, Braidwell LP, Frazier Life Sciences Management, LP, Lighthouse Investment Partners, LLC

Executive VP & Chief Accounting Officer notifies of intention to sell stock

No longer forecast to breakeven

Krystal Biotech, Inc. Receives FDA Approval for the First-Ever Redosable Gene Therapy, Vyjuvek™? (Beremagenegeperpavec-Svdt) for the Treatment of Dystrophic Epidermolysis Bullosa

We Think Krystal Biotech (NASDAQ:KRYS) Can Afford To Drive Business Growth

Price target increased by 7.2% to US$115

No longer forecast to breakeven

Founder notifies of intention to sell stock

Chairman of Scientific Advisory Board notifies of intention to sell stock

Chairman of Scientific Advisory Board notifies of intention to sell stock

Independent Director recently sold US$3.3m worth of stock

Forecast breakeven date moved forward to 2024

We're Hopeful That Krystal Biotech (NASDAQ:KRYS) Will Use Its Cash Wisely

Founder notifies of intention to sell stock

Krystal Biotech, Inc. Announces FDA’s 3-Month Extension of BLA PDUFA Date and Regulatory Update for B-VEC to Treat Patients with Dystrophic Epidermolysis Bullosa

Forecast to breakeven in 2025

Krystal Biotech, Inc. Announces New England Journal of Medicine Publishes Phase 3 Data on B-VEC in Patients with Dystrophic Epidermolysis Bullosa

Founder notifies of intention to sell stock

Founder notifies of intention to sell stock

Krystal Biotech Receives Positive Opinion from EMA Pediatric Committee on the Pediatric Investigation Plan for B-VEC for the treatment of Dystrophic Epidermolysis Bullosa

Krystal Biotech cleared to file EU marketing application for rare skin disease therapy

We Think Krystal Biotech (NASDAQ:KRYS) Can Afford To Drive Business Growth

US Food and Drug Administration Accepts Krystal Biotech’s Biologics License Application for Dystrophic Epidermolysis Bullosa

Krystal Biotech: Solid Performance, Let's Keep Holding

Consensus revenue estimates fall by 90%

Founder notifies of intention to sell stock

Krystal Biotech GAAP EPS of -$1.10 misses by $0.07

Krystal Biotech, Inc. Receives Fda Acceptance of Kb407 Ind Application for Cystic Fibrosis Clinical Trial

Krystal gets FDA nod to start trial of gene therapy KB407 for cystic fibrosis

Krystal Biotech Submits Biologics License Application to U.S. FDA Seeking Approval of B-VEC for the Treatment of Patients with Dystrophic Epidermolysis Bullosa